Effects of MIdazolam versus MOrphine in acute cardiogenic pulmonary edema and chronic obstructive pulmonary disease: An analysis of MIMO trial.

AIMS: Chronic obstructive pulmonary disease (COPD) is an important comorbidity in heart failure. The MIMO trial showed that patients with acute cardiogenic pulmonary edema (ACPE) treated with midazolam had fewer serious adverse events than those treated with morphine. In this post hoc analysis, we examined whether the presence/ absence of COPD modifies the reduced risk of midazolam over morphine. METHODS: Patients >18 years old clinically diagnosed with ACPE and with dyspnea and anxiety were randomized (1:1) at emergency department arrival to receive either intravenous midazolam or morphine. In this post hoc analysis, we calculated the relative risk (RR) of serious adverse events in patients with and without COPD. Calculating the CochranMantel-Haenszel interaction test, we evaluated if COPD modified the reduced risk of serious adverse events in the midazolam arm compared to morphine. RESULTS: Overall, 25 (22.5%) of the 111 patients randomized had a history of COPD. Patients with COPD were more commonly men with a history of previous episodes of heart failure, than participants without COPD. In the COPD group, the RR for the incidence of serious adverse events in the midazolam versus morphine arm was 0.36 (95%CI, 0.1-1.46). In the group without COPD, the RR was 0.44 (95%CI, 0.22-0.91). The presence of COPD did not modify the reduced risk of serious adverse events in the midazolam arm compared to morphine (p for interaction =0.79). CONCLUSIONS: The reduced risk of serious adverse events in the midazolam group compared with morphine is similar in patients with and without COPD.

Midazolam versus morphine in acute cardiogenic pulmonary edema patients with and without atrial fibrillation: findings from the MIMO trial.

BACKGROUND AND IMPORTANCE: The MIMO clinical trial showed that patients with acute cardiogenic pulmonary edema (ACPE) treated with midazolam had fewer serious adverse events than those treated with morphine. Atrial fibrillation (AF) is a common comorbidity in heart failure and affects patient's outcome. OBJECTIVE: The primary endpoint of this substudy is to know if AF modified the reduced risk of serious adverse events in the midazolam arm compared to morphine. The first secondary endpoint is to know if AF modified the reduced risk of serious adverse events or death at 30 days in the midazolam arm. The second secondary objective of this substudy is to analyze whether AF modified the reduced risk of midazolam against morphine on the total number of serious adverse events per patient. DESIGN: We conducted a secondary analysis of the MIMO trial. Patients more than 18 years old clinically diagnosed with ACPE and with dyspnea and anxiety were randomized (1:1) at emergency department arrival to receive either intravenous midazolam or morphine. OUTCOME MEASURES AND ANALYSIS: In this post hoc analysis, we calculated the relative risk (RR) of serious adverse events in patients with and without AF. Calculating the Cochran-Mantel-Haenszel interaction test, we evaluated if AF modified the reduced risk of serious adverse events in the midazolam arm compared to morphine. MAIN RESULTS: One hundred eleven patients (median = 78.9 years; IQR, 72.3-83.7; women, 52.2%) were randomized in the MIMO trial, 55 to receive midazolam and 56 to morphine. All randomized patients received the assigned drug and there were no losses to follow-up. Forty-four patients (39.6%) had AF. In the AF group, the RR for the incidence of serious adverse events in the midazolam versus morphine arm was 0.42 (95% CI, 0.14-1.3). In the group without AF, the RR was 0.46 (95% CI, 0.21-1). The presence of AF did not modify the reduced risk of serious adverse events in the midazolam arm compared with morphine ( P for interaction = 0.88). CONCLUSION: This post hoc analysis of the MIMO trial suggests that the reduced risk of serious adverse events in the midazolam group compared to morphine is similar in patients with and without AF.

Effects of midazolam vs morphine in patients with acute pulmonary edema with left ventricular systolic dysfunction: a secondary analysis of data from the MIMO trial. / Efectos del midazolam frente a la morfina en pacientes con edema agudo de pulmón con disfunción sistólica ventricular izquierda: un análisis secundario del ensayo MIMO.

OBJECTIVES: The midazolam vs morphine (MIMO) trial showed that patients treated with midazolam had fewer serious adverse events than those treated with morphine. In many patients with acute pulmonary edema, the left ventricular ejection fraction (LVEF) is preserved, at 50% or higher. We aimed to determine whether left ventricular (LV) systolic dysfunction (D), defined by an LVEF of less than 50%, modifies the protective effect of midazolam vs morphine. MATERIAL AND METHODS: The MIMO trial randomized 111 patients with acute pulmonary edema to receive intravenous midazolam in 1-mg doses to a maximum of 3 mg (n = 55) or morphine in 2- to 4-mg doses to a maximum of 8 mg (n= 56). We calculated the relative risk (RR) for a serious adverse event in patients with and without systolic LVD. RESULTS: LVEF was preserved in 84 (75.7%) of the patients with acute pulmonary edema. In patients with systolic LVD, 4 patients (26.9%) in the midazolam arm vs 6 (50%) in the morphine arm developed serious adverse events (RR, 0.53; 95% CI, 0.2-1.4). In patients without systolic LVD, 6 patients (15%) in the midazolam arm vs 18 (40.9%) in the morphine arm experienced such events (RR, 0.37; 95% CI, 0.16-0.83). The presence of systolic LVD did not modify the protective effect of midazolam on serious adverse effects (P=.57). CONCLUSION: The effect of midazolam vs morphine in protecting against the development of serious adverse events or death is similar in patients with and without systolic LVD.

OBJETIVO: El ensayo clínico MIMO demostró que los pacientes con edema agudo de pulmón (EAP) tratados con midazolam tenían menos eventos adversos graves (EAG) que los tratados con morfina. Muchos pacientes con EAP tienen fracción de eyección del ventrículo izquierdo (FEVI) preservada ($ 50%). El objetivo fue conocer si la disfunción sistólica ventricular izquierda (DSVI) (fracción eyección ventrículo izquierdo 50%) modifica el efecto protector del midazolam frente a la morfina. METODO: El estudio MIMO asignó al azar 111 pacientes con EAP a tratamiento con midazolam (dosis de 1 mg intravenosa, hasta una dosis máxima de 3 mg, n = 55) o morfina (dosis de 2-4 mg, hasta una dosis máxima de 8 mg, n = 56). Se calculó el riesgo relativo (RR) de padecer un EAG en pacientes con y sin DSVI. RESULTADOS: La FEVI preservada estuvo presente en 84 (75,7%) pacientes con EAP. En el grupo con DSVI, 4 pacientes (26,9%) en el brazo midazolam frente a 6 (50%) en el brazo morfina presentaron EAG (RR = 0,53; IC 95: 0,2-1,4). En el grupo sin DSVI 6 pacientes (15%) del brazo midazolam frente a 18 (40,9%) del brazo morfina presentaron EAG (RR = 0,37; IC 95: 0,16-0,83). La DSVI no modificó el efecto protector del midazolam en la aparición de EAG con respecto a la morfina (p = 0,57). CONCLUSIONES: En pacientes con EAP el efecto protector del midazolam sobre la morfina en la aparición de EAG y EAG o muerte fue similar en pacientes con y sin DSVI.

Efectos del midazolam frente a la morfina en pacientes con edema agudo de pulmón con disfunción sistólica ventricular izquierda: un análisis secundario del ensayo MIMO / Effects of midazolam vs morphine in patients with acute pulmonary edema with left ventricular systolic dysfunction: a secondary analysis of data from the MIMO trial

Objetivo. El ensayo clínico MIMO demostró que los pacientes con edema agudo de pulmón (EAP) tratados con midazolam tenían menos eventos adversos graves (EAG) que los tratados con morfina. Muchos pacientes con EAP tienen fracción de eyección del ventrículo izquierdo (FEVI) preservada ($ 50%). El objetivo fue conocer si la disfunción sistólica ventricular izquierda (DSVI) (fracción eyección ventrículo izquierdo < 50%) modifica el efecto protector del midazolam frente a la morfina.Método. El estudio MIMO asignó al azar 111 pacientes con EAP a tratamiento con midazolam (dosis de 1 mg intravenosa, hasta una dosis máxima de 3 mg, n = 55) o morfina (dosis de 2-4 mg, hasta una dosis máxima de 8 mg, n = 56). Se calculó el riesgo relativo (RR) de padecer un EAG en pacientes con y sin DSVI.Resultado. La FEVI preservada estuvo presente en 84 (75,7%) pacientes con EAP. En el grupo con DSVI, 4 pacientes (26,9%) en el brazo midazolam frente a 6 (50%) en el brazo morfina presentaron EAG (RR = 0,53; IC 95: 0,2-1,4). En el grupo sin DSVI 6 pacientes (15%) del brazo midazolam frente a 18 (40,9%) del brazo morfina presentaron EAG (RR = 0,37; IC 95: 0,16-0,83). La DSVI no modificó el efecto protector del midazolam en la aparición de EAG con respecto a la morfina (p = 0,57)Conclusiones. En pacientes con EAP el efecto protector del midazolam sobre la morfina en la aparición de EAG y EAG o muerte fue similar en pacientes con y sin DSVI. (AU)

Background and objective. The midazolam vs morphine (MIMO) trial showed that patients treated with midazolam had fewer serious adverse events than those treated with morphine. In many patients with acute pulmonary edema, the left ventricular ejection fraction (LVEF) is preserved, at 50% or higher. We aimed to determine whether left ventricular (LV) systolic dysfunction (D), defined by an LVEF of less than 50%, modifies the protective effect of midazolam vs morphine. Methods. The MIMO trial randomized 111 patients with acute pulmonary edema to receive intravenous midazolam in 1-mg doses to a maximum of 3 mg (n = 55) or morphine in 2- to 4-mg doses to a maximum of 8 mg (n= 56). We calculated the relative risk (RR) for a serious adverse event in patients with and without systolic LVD. Results. LVEF was preserved in 84 (75.7%) of the patients with acute pulmonary edema. In patients with systolic LVD, 4 patients (26.9%) in the midazolam arm vs 6 (50%) in the morphine arm developed serious adverse events (RR, 0.53; 95% CI, 0.2-1.4). In patients without systolic LVD, 6 patients (15%) in the midazolam arm vs 18 (40.9%) in the morphine arm experienced such events (RR, 0.37; 95% CI, 0.16-0.83). The presence of systolic LVD did not modify the protective effect of midazolam on serious adverse effects (P=.57). Conclusions. The effect of midazolam vs morphine in protecting against the development of serious adverse eventsor death is similar in patients with and without systolic LVD. (AU)

Reemplazar o no la patela. ¿Cuándo y por qué? / Replace or not the patella. When and why?

Cambiar, o no, la patela ha sido motivo de controversia durante muchos años. Las complicaciones asociadas al aparato extensor y el dolor anterior de rodilla representan un problema recurrente en la cirugía protésica de rodilla. En prótesis total de rodilla (PTR) nos encontramos con tres principales posibilidades: siempre cambiar la patela, nunca cambiarla, o hacer un recambio selectivo dependiendo de las características del paciente. En caso de no realizar recambio, se han descripto procedimientos asociados como la pateloplastia o la denervación de la patela. Y los autores que postulan recambio selectivo han evidenciado diversos factores que ayudarían a tomar la decisión, tales como el índice de masa corporal, grado de artrosis, edad, o anatomía patelar, entre otros. Existe una vasta cantidad de publicaciones científicas en torno al recambio patelar. En esta revisión de la literatura se discutirá qué dice la evidencia respecto de las opciones descriptas (recambio selectivo, siempre o nunca) y se concluirá con la opinión de los autores sobre lo más adecuado según la evidencia

Whether to change the patella, or not, has been a matter of controversy for many years. Complications associated with the extensor apparatus and anterior knee pain represent a recurring problem in knee replacement surgery.In total knee prosthesis (TKP) we find three main possibilities: always change the patella, never change it, or make a selective replacement depending on the patient characteristics. If replacement is not performed, associated procedures such as patelloplasty or patella denervation have been described. And the authors who postulate selective replacement have evidenced various factors that would help to make the decision, such as: body mass index, osteoarthritis degree, age, or patellar anatomy, among others.There is a vast number of scientific publications on patellar turnover. In this review of the literature, we will discuss what the evidence says regarding the options described (selective replacement, always or never) and it will conclude with the opinion of the authors on what is most appropriate according to the evidence

Short-term outcomes by chronic betablocker treatment in patients presenting to emergency departments with acute heart failure: BB-EAHFE.

AIMS: To evaluate the association between chronic treatment with betablockers (BB) and the severity of decompensation and short-term outcomes of patients with acute heart failure (AHF). METHODS AND RESULTS: We consecutively included all patients presenting with AHF to 45 Spanish emergency departments (ED) during six different time-periods between 2007 and 2018. Patients were stratified according to whether they were on chronic treatment with BB at the time of ED consultation. Those receiving BB were compared (adjusted odds ratio-OR-with 95% confidence interval-CI-) with those not receiving BB group in terms of in-hospital and 7-day all-cause mortality, need for hospitalization, and prolonged length of stay (≥7 days). Among the 17 923 recruited patients (median age: 80 years; 56% women), 7795 (43%) were on chronic treatment with BB. Based on the MEESSI-AHF risk score, those on BB were at lower risk. In-hospital mortality was observed in 1310 patients (7.4%), 7-day mortality in 765 (4.3%), need for hospitalization in 13 428 (75.0%), and prolonged length of stay (43.3%). After adjustment for confounding, those on chronic BB were at lower risk for in-hospital all-cause mortality (OR = 0.85, 95% CI = 0.79-0.92, P < 0.001); 7-day all-cause mortality (OR = 0.77, 95% CI = 0.70-0.85, P < 0.001); need for hospitalization (OR = 0.89, 95% CI = 0.85-0.94, P < 0.001); prolonged length of stay (OR = 0.90, 95% CI = 0.86-0.94, P < 0.001). A propensity matching approach yielded consistent findings. CONCLUSION: In patients presenting to ED with AHF, those on BB had better short-term outcomes than those not receiving BB.

Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open-label, randomized controlled trial.

AIMS: Benzodiazepines have been used as safe anxiolytic drugs for decades and some authors have suggested they could be an alternative for morphine for treating acute cardiogenic pulmonary oedema (ACPE). We compared the efficacy and safety of midazolam and morphine in patients with ACPE. METHODS AND RESULTS: A randomized, multicentre, open-label, blinded endpoint clinical trial was performed in seven Spanish emergency departments (EDs). Patients >18 years old clinically diagnosed with ACPE and with dyspnoea and anxiety were randomized (1:1) at ED arrival to receive either intravenous midazolam or morphine. Efficacy was assessed by in-hospital all-cause mortality (primary endpoint). Safety was assessed through serious adverse event (SAE) reporting, and the composite endpoint included 30-day mortality and SAE. Analyses were made on an intention-to-treat basis. The trial was stopped early after a planned interim analysis by the safety monitoring committee. At that time, 111 patients had been randomized: 55 to midazolam and 56 to morphine. There were no significant differences in the primary endpoint (in-hospital mortality for midazolam vs. morphine 12.7% vs. 17.9%; risk ratio[RR] 0.71, 95% confidence interval [CI] 0.29-1.74; p = 0.60). SAE were less common with midazolam versus morphine (18.2% vs. 42.9%; RR 0.42, 95% CI 0.22-0.80; p = 0.007), as were the composite endpoint (23.6% vs. 44.6%; RR 0.53, 95% CI 0.30-0.92; p = 0.03). CONCLUSION: Although the number of patients was too small to draw final conclusions and there were no significant differences in mortality between midazolam and morphine, a significantly higher rate of SAEs was found in the morphine group.

La artroplastía total bilateral de rodilla en un acto anestésico. Un procedimiento seguro, comparable a la artroplastía de rodilla unilateral / Bilateral total knee arthroplasty is a safe procedure compared to unilateral total knee arthroplasty

Introducción: El objetivo de este trabajo es comparar los resultados clínicos y complicaciones de la artroplastia total de rodilla bilateral (ATRB) con los de la artroplastia total de rodilla unilateral (ATRU).Materiales y métodos: estudio caso control. Se analizaron quince pacientes (treinta rodillas) con ATRB y ciento dos con ATRU, operados entre marzo del 2016 a agosto del 2018 por un mismo equipo quirúrgico, centro y modelo de prótesis. Se excluyeron artroplastias con componentes constreñidos. Se analizaron los datos demográficos, estadía hospitalaria (EH), caída del hematocrito, necesidad de transfusión sanguínea, días con drenaje, complicaciones postoperatorias, mortalidad, tiempo de isquemia y rango de movilidad (ROM). Se utilizó la encuesta KOOS Jr. para medir resultados funcionales y otra para valorar satisfacción. El análisis estadístico se realizó con t de Student, prueba exacta de Fisher y modelos mixtos (p <0.05).Resultados: ambos grupos fueron comparables en edad, IMC, tabaquismo, riesgo anestésico según la Sociedad Americana de Anestesiología (ASA), depresión y hematocrito. El grupo ATRB presentó una EH, días de drenaje, descenso del hematocrito postoperatorio y necesidad de transfusiones significativamente mayor. No hubo diferencias significativas en cuanto a tiempo de isquemia, complicaciones postoperatorias, mortalidad y en el ROM logrado a corto y mediano plazo. Se observó una tendencia a lograr antes el ROM objetivo (0-120°) en las ATRB. No hubo diferencias significativas en los resultados funcionales ni en satisfacción. Conclusión: en nuestro centro y en pacientes seleccionados, la ATRB es un procedimiento seguro sin una mayor tasa de complicaciones ni mortalidad asociada, con resultados clínicos similares a la ATRU. Nivel de Evidencia: III

Introduction: The aim of this study is to compares the clinical results and complications of bilateral total knee arthroplasty (BTKA) with unilateral total knee arthroplasty (UTKA).Materials and methods: case control study. Fifteen patients (thirty knees) with BTKA and hundred two patients with UTKA were analyzed, operated from March 2016 to August 2018 by the same surgical team, center and prosthetic model. Arthroplasties with constrained components were excluded. Demographic data, length of hospital stay (LOS), hematocrit drop, need for blood transfusion, days with drainage, post-operative complications, mortality, tourniquet time and range of motion (ROM) were analyzed. KOOS Jr. survey was answered, and satisfaction was reported. Statistical analysis was performed with t-Student, Fisher's test and mixed models (p <0.05).Results: the groups were comparable (age, BMI, smoking, anesthetic risk according to the classification system of the American Society of Anesthesiology (ASA), depression, hematocrit). The BTKA group presented LOS, drainage days, decrease in post operative hematocrit and need for transfusions significantly higher. There were no significant differences in terms of tourniquet time, post-operative complications, mortality and ROM achieved at short term. There is a tendency to achieve the target ROM (0-120 °) earlier on the BTKA group. There were no significant differences in functional results or satisfaction.Conclusion: In our center and in selected patients, the BTKA is a safe procedure without a higher rate of complications or associated mortality, with clinical results similar to the UTKA. Level of Evidence: III

Manejo no quirúrgico de la artrosis de rodilla: ¿Son efectivos los medicamentos orales complementarios? / Non-surgical management of knee osteoarthritis: are complementary oral medications effective?

La artrosis es una enfermedad progresiva de las articulaciones sinoviales que causa dolor, impotencia funcional, discapacidad, y degeneración progresiva de la articulación. En sus tratamientos, sobre todo en etapas tempranas, existen distintas intervenciones para evitar tanto su desarrollo y progresión como también para lograr un adecuado manejo de los síntomas, y hay tratamientos médicos orales no convencionales con evidencia controvertida. El objetivo de este trabajo es proporcionar una actualización, dirigida a especialistas en Ortopedia y Traumatología, respecto a la evidencia actual sobre las terapias complementarias orales en el tratamiento de la artrosis de rodilla. Se hace referencia a los métodos fármacológicos complementarios más usados y estudiados, mencionando el método de acción y las consecuencias estudiadas sobre la artrosis de rodilla. Se finaliza con una tabla de recomendaciones basada en evidencia actual.

Osteoarthritis (OA) is a progressive disease of the synovial joints that causes pain, functional impairment, disability, and progressive degeneration of the joint. Regarding its treatments, especially in early stages, there are different interventions to avoid its development and progression and also to achieve an adequate management of symptoms, and there are unconventional oral medical treatments with controversial evidence. The objective of the present paper is to provide an update, to specialists in Orthopedics and Traumatology, regarding the current evidence on complementary oral therapies in the treatment of knee osteoarthritis. References are made to the most widely used and studied complementary pharmacological methods, mentioning the method of action and the consequences studied on knee osteoarthritis. The article ends with a table of recommendations based on current evidence.

High-Grade Patellar Chondral Defects: Promising Results From Management With Osteochondral Autografts.

BACKGROUND: Patellar chondral defects represent up to 34.6% of defects found during routine arthroscopy. Surgical management has evolved during the past 20 years in an effort to develop techniques to replace hyaline cartilage. Currently, the only technique that achieves this is osteochondral autologous transfer (OAT). Although good and excellent results have often been reported at midterm and long-term follow-up for femoral lesions, little is known about isolated patellar defects. PURPOSE: To assess clinical and imaging results of patients treated with OAT for high-grade patellar defects. STUDY DESIGN: Case series; Level of evidence, 4. METHODS: This was a retrospective study on all patients who received OAT for high-grade symptomatic patellar chondral defects between 2010 and 2018 at our institution. The study included patients younger than 40 years of age with anterior knee pain and a grade 4 International Cartilage Repair Society patellar chondral defect between 1 and 2.5 cm2. Patients with surgery in other knee compartments, concomitant anterior cruciate ligament ruptures, infection, rheumatoid arthritis, and degenerative lesions were excluded. Six months postoperatively, all patients underwent magnetic resonance imaging (MRI) to allow assessment of graft integrity via the MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) score to evaluate morphologic features and integration. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Kujala scores were used to assess functional outcomes at final follow-up. RESULTS: A total of 26 patients who received a patellar OAT were included. Most patients were male (88.4%), and the mean ± SD age was 28.5 ± 9.7 years. Patellar chondral defects had a median size of 180 mm2 (range, 64-250 mm2), and patients received a median of 1 autograft (range, 1-3). Functional outcomes assessed at a minimum of 1 year after surgery showed a mean Kujala score of 90.42 ± 6.7 and a mean WOMAC score of 95 ± 3.6. MRI revealed a median MOCART score of 75 points (range, 20-90 points). CONCLUSION: To our knowledge, this is the largest series to date regarding isolated patellar OAT. At midterm follow-up, most patients reported good and excellent results regarding symptoms and activity levels. Most autografts showed good osseous integration and excellent filling of the chondral surface, as evidenced on MRI. OAT is a good alternative to treat high-grade patellar chondral defects, especially among young patients.

¿Son reversibles los fenómenos degenerativos del cuádriceps al reparar diferidamente una lesión del tendón patelar? / Are quadriceps degenerative phenomena reversible when delayed repair of a patellar tendon injury?

En este trabajo evaluaremos si existe regresión de los cambios degenerativos del cuádriceps tras la reparación diferida de una lesión del aparato extensor. La hipótesis es que esta reparación diferida favorece la regresión de cambios degenerativos del cuádriceps, relacionado con la precocidad de la reparación.Estudio experimental en quince ratones BKS machos: se seccionaron completamente ambos tendones patelares. Se definieron tres grupos de cinco animales cada uno, randomizados, según el momento en que se reparó el tendón derecho: Grupo 1: una semana postsección; Grupo 2: dos semanas; y Grupo 3: cuatro semanas postsección. El cuádriceps izquierdo, no reparado, se utilizó como control respectivo para cada grupo. Los animales fueron sacrificados a las cuatro semanas post-reparación. Un patólogo, ciego al estudio, analizó las características macroscópicas e histológicas. El análisis estadístico incluyó test para muestras pareadas e independientes (p<0.05).Macroscopia: hubo tres reparaciones fallidas, dos en el grupo 2 y una en el grupo 3. Solo se observaron diferencias significativas en la longitud cuadricipital del grupo 1 versus su control (p= 0.0422). No hubo diferencias estadísticas entre los grupos de intervención, ni contra los controles respectivos en los otros parámetros evaluados.Histología: no se encontraron diferencias estadísticamente significativas entre los grupos de intervención, ni contra sus controles respectivos.En este modelo experimental, la reparación diferida de una lesión completa del aparato extensor de la rodilla no demostró una reversibilidad de los cambios degenerativos musculares. La precocidad de la reparación se relacionó con menor número de fallas y mayor longitud cuadricipital. Se refuerza la importancia de priorizar la reparación temprana de lesiones completas del aparato extensor de la rodilla

Evaluate the regression of degenerative changes in the quadricipital muscle after a delayed extensor mechanism repair. The hypothesis is that a delayed repair favors the regression of degenerative changes related to the precocity of the repair. Experimental study in fifteen BKS male mice: a complete section of both patellar tendons was made. Animals were randomly divided into three study groups (five mice per group), according to the week after the lesions at which the right quadriceps were repaired: Group 1: one week; Group 2: two weeks, and Group 3: four weeks. Left quadriceps remained unrepaired and was used as the corresponding control for each group. All animals were sacrificed four weeks after the repair. A blind pathologist analyzed macroscopic and histologic evaluations. Statistical analysis included tests for paired and independent samples (p=0.05).Macroscopy: there were three repair failures, two in group 2 and one in group 3. Quadricipital length in group 1 was the only significant difference (p=0.04222) observed between the intervened muscles and their corresponding control. No statistical differences were present between the intervention groups, neither when compared to their corresponding controls for the other macroscopic parameters. Histology: No statistical differences were present between the intervention groups, neither when compared to their corresponding controls for the other macroscopic parameters.A delayed repair of a complete knee extensor mechanism injury in this experimental model did not demonstrate the regression of the degenerative muscle changes. The precocity of the repaired correlated with fewer repair failures and a greater quadricipital length. The present experimental study enhances the importance of an early repair for complete knee extensor mechanism injury

¿Podemos mejorar la cicatrización de un desgarro muscular masivo? / Can we improve the healing of a massive muscle tear?

OBJETIVOS: Evaluar macroscópica e histológicamente la cicatrización muscular utilizando Dexametasona (DEX) o Traumeel (TRM), en un modelo experimental animal. MATERIAL Y MÉTODOS: Estudio experimental en 45 ratones BKS. Se seccionó transversal y completamente el cuádriceps derecho en todos los animales. Se definieron 3 grupos de estudio de 15 ratones cada uno, un grupo control, un grupo tratado con Dexametasona y uno con Traumeel. Los animales fueron sacrificados a las 1,2 y 4 semanas después del procedimiento y se les extrajo ambos cuádriceps (derecho como intervención e izquierdo como control) y luego fueron analizados macroscópica e histológicamente por un patólogo calificado, de manera ciega. Los datos se analizaron estadísticamente con el test de Kruskal - Wallis (p < 0,05), utilizando el programa Stata V12.1. RESULTADOS: Macroscopía: A la semana, en todos los grupos se evidenció ausencia de cicatrización con gap persistente. A la segunda semana, se evidencia cicatrización inicial sin gap en todos los grupos. A las 4 semanas todas las muestras estaban cicatrizadas. HISTOLOGÍA: La administración de Dexametasona disminuye el infiltrado inflamatorio y aumenta las fibras regenerativas, pero induce mayor fibrosis y pérdida de masa muscular. La adición de Traumeel aumenta la cantidad de fibras regenerativas, pero incrementa el infiltrado inflamatorio. CONCLUSIONES: A las 4 semanas ninguno de los grupos de estudio presentó regeneración muscular completa, con resultados macroscópicos e histológicos variables.

OBJETIVES: To macroscopically and histologically evaluate a muscle strain healing model, using Dexamethasone and Traumeel. MATERIALS AND METHODS: Experimental study in 45 BKS mice. 3 groups of 15 mice were defined: control group, Dexamethasone treated group and Traumeel treated group. The animals were sacrificed at the 1st, 2nd and 4th week, both quadriceps were resected (right as intervention and left as control) and then analyzed macroscopically and histologically by a qualified and blinded pathologist. Results were analyzed statistically using Kruskal - Wallis test (p<0.05). RESULTS: Macroscopy: the first week, all groups showed absence of healing with persistent gap. At the 2nd week, evidence of initial healing without gap in all groups. By week 4, all samples were healed. HISTOLOGY: Dexamethasone decreased the inflammatory infiltration and increased the regenerative fibers, but induced a higher fibrosis and loss of muscle mass. Traumeel increased the amount of regenerative fibers and the inflammatory infiltration. DISCUSSION: The results of our study fail to define a definitive posture. We observed that Traumeel actually increases the amount of regenerative fibers and contrary to the literature, it increases the inflammatory infiltrate. On the other hand, Dexamethasone showed similar results in both regenerative fibers, fatty infiltration and muscle mass, but with increased necrosis. CONCLUSIONS By the 4th week none of the groups showed complete muscle regeneration with macroscopic and histological variable results.

Utilidad de los biomarcadores en el manejo del dolor abdominal / Utility of biomarkers in abdominal pain management

Las manifestaciones de las enfermedades que subyacen bajo el término de dolor abdominal agudo (DAA) como motivo de consulta en urgencias, pueden ser sutiles en su inicio y variables en el tiempo, lo que dificulta su reconocimiento precoz. Entre ellas son prioritarias las englobadas bajo el término de abdomen agudo (AA) o situación de DAA tiempo-dependiente. Los biomarcadores pueden mejorar el manejo de estos pacientes, añadiendo información adicional a la valoración clínica y a las exploraciones complementarias, e incrementando la capacidad diagnóstica y pronóstico. Los biomarcadores más utilizados en urgencias son la proteína C reactiva (PCR), la procalcitonina (PCT) y el lactato. La PCR ha sido el marcador más estudiado en el diagnóstico del DAA, y es muy difícil establecer un punto de corte que proporcione buena sensibilidad y especificidad. La PCT es el biomarcador más sensible y adecuado, gracias a su particular cinética, para valorar la gravedad antes de que los signos clínicos de sepsis grave o alteración hemodinámica hagan su aparición. El lactato es un marcador de hipoperfusión tisular y elemento clave en el manejo de la sepsis grave y del shock séptico en el abdomen agudo, lo que añadido a su fácil y rápida obtención y a su bajo coste, definen su importancia y utilidad en los servicios de urgencias (AU)

Abdominal pain conditions that fall into the category of acute abdomen (AA) are the most important ones to identify quickly. Diagnostic delay can lead to death or significant complications. Biological markers have the potential to improve the diagnostic and prognostic capacity of clinical assessment and the conventional complement of tests. This review aims to explore the relevance of several markers to the management of AA in the emergency department. Creactive protein (CRP), procalcitonin, and lactate are the biomarkers most often used in the emergency department. CRP is often analyzed in the context of AA, but it is very difficult to establish a cutoff that gives good sensitivity and specificity. The kinetics of CRP make it the most sensitive biomarker and one that is appropriate for assessing severity before the onset of clinical signs of severe sepsis or altered hemodynamics. Lactate is a marker of poor tissue perfusion, a key element in the management of severe sepsis and septic shock in AA. Since lactate testing is easy and inexpensive, this important biomarker is useful in the emergency department (AU)

[Utility of biomarkers in abdominal pain management]. / Utilidad de los biomarcadores en el manejo del dolor abdominal.

EN: Abdominal pain conditions that fall into the category of acute abdomen (AA) are the most important ones to identify quickly. Diagnostic delay can lead to death or significant complications. Biological markers have the potential to improve the diagnostic and prognostic capacity of clinical assessment and the conventional complement of tests. This review aims to explore the relevance of several markers to the management of AA in the emergency department. Creactive protein (CRP), procalcitonin, and lactate are the biomarkers most often used in the emergency department. CRP is often analyzed in the context of AA, but it is very difficult to establish a cutoff that gives good sensitivity and specificity. The kinetics of CRP make it the most sensitive biomarker and one that is appropriate for assessing severity before the onset of clinical signs of severe sepsis or altered hemodynamics. Lactate is a marker of poor tissue perfusion, a key element in the management of severe sepsis and septic shock in AA. Since lactate testing is easy and inexpensive, this important biomarker is useful in the emergency department.

ES: Las manifestaciones de las enfermedades que subyacen bajo el término de dolor abdominal agudo (DAA) como motivo de consulta en urgencias, pueden ser sutiles en su inicio y variables en el tiempo, lo que dificulta su reconocimiento precoz. Entre ellas son prioritarias las englobadas bajo el término de abdomen agudo (AA) o situación de DAA tiempo-dependiente. Los biomarcadores pueden mejorar el manejo de estos pacientes, añadiendo información adicional a la valoración clínica y a las exploraciones complementarias, e incrementando la capacidad diagnóstica y pronóstico. Los biomarcadores más utilizados en urgencias son la proteína C reactiva (PCR), la procalcitonina (PCT) y el lactato. La PCR ha sido el marcador más estudiado en el diagnóstico del DAA, y es muy difícil establecer un punto de corte que proporcione buena sensibilidad y especificidad. La PCT es el biomarcador más sensible y adecuado, gracias a su particular cinética, para valorar la gravedad antes de que los signos clínicos de sepsis grave o alteración hemodinámica hagan su aparición. El lactato es un marcador de hipoperfusión tisular y elemento clave en el manejo de la sepsis grave y del shock séptico en el abdomen agudo, lo que añadido a su fácil y rápida obtención y a su bajo coste, definen su importancia y utilidad en los servicios de urgencias.

[Isokinetic assessment post-ACL reconstruction: comparison of the semitendinous/gracilis and bone-tendon-bone techniques]. / Evaluación isocinética postreconstruccióón de ligamento cruzado anterior: comparación de dos técnicas.

UNLABELLED: The purpose of this study is to detect the differences in the isokinetic assessment after anterior cruciate ligament (ACL) reconstruction with the bone-patellar tendon-bone (BTB) and semitendinous/gracilis (STG) techniques. METHODS: Ninety-five patients with a minimum follow-up of six months were assessed with a Cybex 6000 dynamometer during concentric contraction at 60 degrees/s. The BTB technique was used in 27 patients and the STG technique in 68. The ANOVA and Pearson tables were used to analyze the flexion and extension strength deficit, peak torque (PT) strength in flexion and extension (Nm) and the muscle balance. RESULTS: Mean loss of strength in flexion was 18.82% with BTB and 11.05% with STG (p = 0.04). Mean loss of strength in extension was 24.04% with BTB and 17.1% with STG (p = 0.75). The mean PT strength in flexion was 113.2 Nm (38-203) for BTB and 128.4 Nm (73-219) for STG (p = 0.603). The mean PT strength in extension was 187.2 Nm (68-363) for BTB and 194 Nm (107-339) for STG (p = 0.102). The mean muscle balance was 73.4% for STG and 68.6% for BTB (p = 0.961). CONCLUSION: The flexion strength was more compromised after BTB reconstruction compared to the STG procedure. We documented a trend towards loss of PT strength in flexion and extension and muscle balance with flexor predominance post-BTB reconstruction.

Mixoma auricular. A propósito de un caso / Atrial myxoma. A propos of a case

No disponible